Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study

Health-related quality of life (HRQoL) is impaired in multiple sclerosis (MS) but can be improved by disease-modifying therapies such as natalizumab. However, the predictive factors and neuropsychiatric correlates of HRQoL improvement are unknown. In this study, 48 patients with relapsing-remitting...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the neurological sciences 2017-11, Vol.382, p.148-154
Main Authors: Planche, Vincent, Moisset, Xavier, Morello, Remy, Dumont, Emilie, Gibelin, Marion, Charré-Morin, Julie, Saubusse, Aurore, Mondou, Audrey, Reuter, Françoise, Defer, Gilles, Pelletier, Jean, Brochet, Bruno, Clavelou, Pierre
Format: Article
Language:English
Subjects:
Adult
Cognition
Depression
Disability Evaluation
Disease Progression
Fatigue
Fatigue - drug therapy
Fatigue - physiopathology
Fatigue - psychology
Female
Follow-Up Studies
Health-related quality of life
Humans
Immunologic Factors - therapeutic use
Life Sciences
Male
Multiple sclerosis
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Multiple Sclerosis, Relapsing-Remitting - physiopathology
Multiple Sclerosis, Relapsing-Remitting - psychology
Natalizumab
Natalizumab - therapeutic use
Neurons and Cognition
Neuropsychological Tests
Quality of Life
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Health-related quality of life (HRQoL) is impaired in multiple sclerosis (MS) but can be improved by disease-modifying therapies such as natalizumab. However, the predictive factors and neuropsychiatric correlates of HRQoL improvement are unknown. In this study, 48 patients with relapsing-remitting MS were included in a 3-year open-label, single group, multicenter, clinical trial (NCT01392872). HRQoL was measured by the disease-specific MusiQoL questionnaire, together with physical disability, cognition, fatigue, anxiety and depression scores at baseline, 6months, 12months, 18months and 36months after starting natalizumab therapy. Compared to baseline, global HRQoL, as measured with the index of the MusiQoL, was significantly increased 6months after the beginning of natalizumab therapy, with medium effect-size (58.6±16.2 vs 69.8±18.9, p
ISSN:0022-510X
1878-5883
DOI:10.1016/j.jns.2017.10.008